Affymax (AFFY -0.3%) CEO John Orwin says the days of biotech companies seeing their share price...
Affymax (AFFY -0.3%) CEO John Orwin says the days of biotech companies seeing their share price bid up on potential is over, as investors wait it out to see if firms hash out issues with reimbursements, regulatory hurdles, and safety concerns. "There was a time when products got full value prior to launch. I think we have now swung back in the other direction."
From other sites
at MarketWatch.com (Jun 3, 2013)
at CNBC.com (May 31, 2013)
at MarketWatch.com (Apr 2, 2013)
at MarketWatch.com (Mar 19, 2013)
at CNBC.com (Mar 19, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs